Current dosing regimens of psychotropic drugs are based on plasma kinetic considerations, although it is unclear whether plasma levels faithfully reflect brain kinetics of drugs.
Novel antipsychotics are currently used to treat diverse medical conditions such as schizophrenia, mania, depression, and dementia. It is well established that antagonism of D 2 receptors is critical for antipsychotic efficacy, 3, 4 and that at clinical doses antipsychotics block a substantial proportion of D 2 receptors in vivo. 5 Positron emission tomography and selective ligands such as [ 11 C]raclopride have provided valuable insights regarding receptor occupancy during treatment with olanzapine and risperidone. 6, 7 However, in most studies PET scans were obtained only at a single time point after medication intake, typically 12 h post-dose. Hence, little is known about the time course of brain receptor blockade with these atypical antipsychotics. This is of particular interest as it has been shown that D 2 receptor occupancy can persist up to 15 days after withdrawal from oral doses of conventional neuroleptics, 8 and up to 6 months after depot injection of haloperidol decanoate. 9 We measured the time course of drug plasma levels and brain D 2 receptor occupancy in healthy volunteers after a single dose of 3-4 mg risperidone (n = 4) or 15 mg olanzapine (n = 4). We used [ 11 C]raclopride as a PET-ligand to estimate central D 2 receptor occupancy in the striatum, 1 and [ 11 C]FLB457 for quantification of extra-striatal D 2 blockade in the thalamus. 10 Additionally, we investigated the time course of plasma levels and striatal D 2 occupancy in five stable patients suffering from schizophrenia. These patients had received a monotherapy with olanzapine 15-20 mg day −1 (n = 3) or risperidone 3 mg day −1 (n = 2) for at least one month. We scanned them immediately after withdrawal from their antipsychotic medication, and again after 24 and 48 h.
In the single-dose experiments in healthy volunteers, mean peak olanzapine plasma levels occurred 6 h after intake (23 ng ml −1 ± 4 SD). The plasma elimination half-life time (t 1/2 ) was 24.2 h (95% confidence interval (CI): 21.2-28.1). After 72 h, plasma levels declined on Figure 1 Single dose experiments in controls. Time course of plasma levels (olanzapine: , grey dashed line; risperidone plus 9-OH-risperidone: , grey solid line), and striatal D 2 receptor occupancy (olanzapine: , black dashed line; risperidone: , black solid line). All results are normalized to 100% of their peak value. Error bars denote one standard deviation.
Molecular Psychiatry average to 4 ng ml −1 , corresponding to 19% of the peak plasma level (Figure 1 ). The active moiety of risperidone, risperidone plus 9-hydroxyrisperidone, peaked on average after 2 h (37 ng ml −1 ± 14 SD), reached t 1/2 after 10.3 h (95% CI: 8.1-14.3) and declined to 5% of peak levels within 72 h (Figure 1 ). The observed plasma kinetics were in close correspondence to previously reported results obtained in healthy volunteers [11] [12] [13] and patients with schizophrenia.
14 Both single doses of risperidone and olanzapine led to high striatal D 2 receptor blockade, with peak occupancy rates at the time of their respective peak plasma levels ranging from 80-88%. Subsequent serial PET scans revealed sustained D 2 receptor occupancy with both drugs in the range of 71-77% after 24 h, 56-60% after 48 h, and 36-42% after 72 h. Brain t 1/2 at the striatal D 2 receptor was 75.2 h (95% CI: 67.9-84.4) for a single dose of olanzapine and 66.6 h (95% CI: 54.0-86.8) for risperidone. These brain receptor t 1/2 values of both drugs, observed after only one single dose, are substantially longer than the currently recommended dosing interval of 24 h with both drugs.
In olanzapine-treated patients, plasma-levels peaked at 66 ng ml −1 (±4 SD), showed a t 1/2 of 19.5 h (95% CI: 12.4-45.9), and declined to 16 ng ml −1 (±3 SD) after 48 h, corresponding to 25% of the peak plasma level. After discontinuation of risperidone in patients, plasma levels declined with a t 1/2 of 13.4 h (95% CI: 9.8-20.8) to 16% of their peak values within 48 h ( Figure 2 ).
Continuous treatment with 15-20 mg day −1 olanzapine or 3 mg day −1 risperidone resulted in high striatal D 2 receptor blockade ranging from 81% to 88% at the time of peak plasma levels. Subsequent serial PET scans after discontinuation of the antipsychotic medication revealed mean striatal D 2 occupancy values of 78% with olanzapine and 66% with risperidone after 24 h, and after 48 h 61% with olanzapine and 42% The extra-striatal D 2 receptor occupancy, as measured with [ 11 C]FLB457 and PET in the thalamus, closely resembled the time course seen in the striatum. Single doses of olanzapine or risperidone led to comparably high peak D 2 occupancy of extra-striatal D 2 receptors in the thalamus ranging from 72% to 82% and declining to 51-69% after 24 h, and 27-37% after 72 h. Table 1 shows a synopsis of plasma levels and D 2 receptor occupancy in healthy volunteers and patients.
Each of the healthy volunteers experienced sedation, which was reversible within hours. Additionally, three of the four subjects receiving risperidone showed mild to moderate akathisia, which spontaneously resolved in two cases, and had to be treated with 1 mg of lorazepam in one case. None of the patients reported any clinically relevant side effects at the time of the PET scans.
To examine whether the brain effects of antipsychotics follow a similar time course on other neurotransmitter receptors, and since 5-HT 2A receptors have been implicated in the genesis and treatment of psychosis, 15 we additionally examined the time course of 5-HT 2A receptor occupancy in two healthy volunteers receiving a single dose of 4 mg risperidone or 15 mg olanzapine. Both drugs led to a complete saturation of 5-HT 2A receptors within 6 h. After 48 h risperidone still led to a complete blockade of 5-HT 2A receptors and olanzapine to 92% occupancy, indicating a persisting cortical 5-HT 2A receptor blockade, despite the fact that drug plasma levels had declined to less than 10% of their peak plasma level with both drugs.
In summary, both single doses of olanzapine and risperidone in healthy volunteers and continuous treatment in patients led to substantial and prolonged D 2 and 5-HT 2A receptor occupancy. Plasma drug levels declined significantly faster than brain receptor occupancy. The 95% CI of brain and plasma t 1/2 were distinctly different and non-overlapping for both atypical antipsychotics in single-dose experiments in controls and under steady-state conditions in patients. Thus, our study convincingly demonstrates a significant dissociation of declining drug plasma levels and the time course of brain effects in healthy volunteers and patients, after single doses or continuous treatment with risperidone or olanzapine, and both, in striatal and extra-striatal brain regions.
Several factors may account for the significant difference in the time courses of drug plasma levels and brain receptor occupancy. The relation between plasma drug levels and occupancy is non-linear and can be best described by a rectangular hyperbola. 1 In the case of almost saturated receptors (Ͼ90% occupancy), a 50% reduction of drug plasma concentration translates into a very minor receptor occupancy decline. With lower values for both plasma concentration and occupancy-in the steeper part of the hyperbola-a similar reduction in plasma concen- tration results in a much higher decline of receptor occupancy. This non-linear relationship might explain the prolonged occupancy seen with olanzapine. However, risperidone led to substantial receptor blockade with almost no measurable plasma levels. The presence of longer acting, active metabolites, such as 9-OH-risperidone, or altered brain metabolism of the parent compound may contribute to the prolonged receptor occupancy. 5 In addition, a relatively low dissociation rate at brain receptors may lead to both drugs being attached for a relatively long time to their binding sites, even after plasma levels have declined. 2 Furthermore, the tissue concentration of lipophilic compounds such as olanzapine or risperidone is known to be 4-to 46-fold higher than the plasma concentration in the rat. 16 Therefore, the effective concentration at their molecular target in the human brain is likely much higher than their plasma concentration.
Using PET and [
11 C]-labeled ligands in humans in vivo, we observed sustained brain receptor effects with olanzapine and risperidone: (1) on D 2 and 5-HT 2A receptors; (2) in different brain regions: striatum, thalamus and frontal cortex; (3) after single doses in healthy volunteers; and (4) after discontinuation of these medications in patients suffering from schizophrenia. All four lines of evidence call for a revision of current recommendations and practice to dose risperidone and olanzapine once-or twice-a-day. The finding that brain kinetics are so prolonged is even more important given recent findings that only 'transiently' high D 2 occupancy is sufficient for obtaining 17 and maintaining 18 antipsychotic efficacy. In contrast to constant high antibiotic plasma levels being required for effective treatment of bacterial infections, continuous high D 2 receptor occupancy may not be necessary for antipsychotic efficacy. Quetiapine showed antipsychotic efficacy in
Molecular Psychiatry
patients with schizophrenia despite only transient D 2 receptor occupancy. 17 Furthermore, low-dose treatment with haloperidol decanoate has proven clinical efficacy for relapse prevention in schizophrenic patients, even when the mean D 2 receptor occupancy had decreased to 52% 4 weeks after injection. 18 The clinical efficiency and other benefits of longer dosing intervals, such as a substantial medication cost reduction, need to be examined. While the final answer can only be empirically determined, the current data should lead one to question the conventional approach of relying on plasma elimination half-lives for dosing schedules of antipsychotics. We think that controlled clinical trials based on central neurotransmitter kinetics are warranted to develop innovative and rational dosing schedules for psychotropic medications.
Methods
Ten healthy volunteers (four females, six males; mean age 31.4 ± 7.6 years SD) and five patients with a DSM-IV diagnosis of schizophrenia (five males; mean age 30.5 ± 8.7 years SD) were included after they provided written consent using forms and procedures approved by the University of Toronto Human Subjects Review Committee.
The healthy subjects had no history of psychiatric or neurologic disorder, did not suffer from a significant medical condition or psychiatric axis I disorder, as established by a structured clinical interview (SCID-I/NP), and had not taken any psychotropic medication 3 months prior to this study. All patients were under steady state conditions as they had been treated with an antipsychotic monotherapy in the same dose for at least one month prior to the PET study. Two of the patients received 3 mg day −1 of risperidone and the three other patients were on 15-20 mg day −1 of olanza-pine. All had responded to their medication and were regarded as clinically stable enough to tolerate a 48-h withdrawal from their medication, during which we assessed drug plasma levels and striatal D 2 receptor occupancy. No subject had received any other antipsychotic in the last 3 months prior to this study, and none had received any depot antipsychotics in the year before.
All healthy volunteers underwent a baseline PET scan, either with [
11 C]raclopride to obtain their unmedicated striatal D 2 receptor binding potential (BP) as described in detail elsewhere, 7 or with [ 11 C]FLB 457 10 to calculate their baseline extra-striatal BP in the thalamus, or with [
11 C]setoperone to assess their baseline 5-HT 2A BP in the prefrontal cortex. Subsequently, they were randomly assigned to a single dose of 3-4 mg risperidone (n = 5), or 15 mg olanzapine (n = 5). Medication induced side effects were rated according to the UKU Side Effect Rating Scale. 19 The BP after the subjects had taken their medication was compared to the baseline value obtained before treatment was started, and the proportion of receptors blocked by a drug ('receptor occupancy') was calculated using the following equation:
As we had no baseline value in patients treated with antipsychotics, we used an age-corrected estimate obtained from a separate group of 12 antipsychotic naive patients with schizophrenia and 15 age-matched healthy subjects. This procedure has been described in detail elsewhere. 7 Time courses of the levels of D 2 occupancy were assessed by a series of PET scans over the next 4 days, using images obtained with a GE-2048-15B head scanner using the striatal/cerebellar ratio minus one, obtained with a [
11 C]raclopride bolusplus-infusion protocol, as an estimate for striatal D 2 BP. 7 For the quantification of extra-striatal D 2 BP in the thalamus, we applied a simplified reference tissue model 20 to 60-min time-activity curves obtained with [ 11 C]FLB 457 in the thalamus and the cerebellum. We merged values from both hemispheres for the striatal and the extra-striatal BP quantification. The 5-HT 2A scans were obtained with the use of a bolus injection of high specific activity [ 11 C]setoperone, and 5-HT 2A occupancy was determined in the prefrontal cortex as described in detail elsewhere. 7 In analogy to the term 'plasma elimination half-live' we used the term 'brain elimination half-live' (brain t 1/2 ) to describe the time needed until brain receptor occupancy declined to 50%. In order to compute brain t 1/2 values for striatal, extra-striatal and prefrontal regions, after normalizing time course occupancies to 100% of their respective peak value, we fitted the time courses of receptor occupancy with olanzapine and risperidone to a linear polynomial regression, which can be described as f = (y 0 + a × t (y 0 = intercept; a = slope of occupancy decline; t = time). The r 2 values of the linear regression analyses ranged from 0.95 to 0.99, and their P-values were Ͻ0.05, except for the one describing olanzapine plasma levels in the single dose experiments with healthy subjects (P = 0.14).
We determined olanzapine and risperidone plasma levels using liquid chromatography/mass spectrometry. 21, 22 Risperidone plasma levels were measured by means of a radioimmunoassay for the active moiety, which reflects both risperidone and 9-OH-risperidone. 22 To compute plasma t 1/2 values, we fitted the plasma levels to a nonlinear regression using a single 2-parameter exponential decay function, which can be described as f = a × e −b × t (a = slope of plasma level decline; b = rate constant for elimination from the plasma; t = time). For these exponential decay fits, the r 2 values ranged from 0.90 to 0.99, and all were statistically significant with P-values ranging from Ͻ0.001 to 0.01.
